Compare CRMT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | MBRX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 6.4M |
| IPO Year | 2026 | 2016 |
| Metric | CRMT | MBRX |
|---|---|---|
| Price | $1.10 | $8.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.50 | ★ $240.00 |
| AVG Volume (30 Days) | ★ 590.6K | 328.7K |
| Earning Date | 12-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,281,502,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $0.16 |
| 52 Week High | $28.70 | $15.75 |
| Indicator | CRMT | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 86.94 |
| Support Level | $0.95 | $2.12 |
| Resistance Level | $1.49 | N/A |
| Average True Range (ATR) | 0.23 | 0.71 |
| MACD | 0.03 | 0.79 |
| Stochastic Oscillator | 55.37 | 85.93 |
America's Car-Mart Inc is one of the publicly held automotive retailers in the United States focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The Company mainly sells older model used vehicles and provides financing for substantially all of its customers. The company operates in the Integrated Auto Sales and Finance segment of the used car market. In this industry, the nature of the sale and the financing of the transaction, financing processes, the type of customer and the methods used to distribute the company's products and services, including the actual servicing of the contracts as well as the regulatory environment in which the company operates, all have similar characteristics. The company operates in a single reportable segment.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.